Humira Proves Effective in Treatment of Psoriasis
Posted on: Thursday, 5 October 2006, 15:00 CDT
Abbott Laboratories has said that new research has showed its rheumatoid arthritis drug Humira to be superior to a standard treatment for psoriasis.
Positive phase III data demonstrated that Humira was statistically superior to methotrexate in patients with psoriasis. Patients with moderate to severe psoriasis receiving Abbott's Humira achieved at least 75% improvement in disease, compared to patients receiving methotrexate where it was an improvement of 36%.
This is the first psoriasis study to feature a head-to-head comparison between a biologic agent and a standard systemic treatment.
"The results of this study strongly suggest the potential Humira may have as a new treatment for psoriasis," said the study's primary investigator, Professor Jean-Hilaire Saurat, chairman of the department of dermatology, University of Geneva in Switzerland.
Psoriasis is a chronic, non-contagious autoimmune skin disease characterized by very dry, scaly and cracked skin, skin pain, and patches of red, raised skin known as "plaques". There is currently no cure for the disease, which affects an estimated 125 million people worldwide.
Source: Datamonitor
Related Articles
- ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
- ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
- Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimer's Disease.
- Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to Be Presented at ARVO
- Study Finds C1-Inhibitor Concentrate Is Safe and Effective in Treating Skin Swelling in Patients With Hereditary Angioedema
- TorreyPines Therapeutics Completes Second Phase I Study for NGX267, a Selective M1 Agonist for the Treatment of Alzheimer's Disease
- TorreyPines Therapeutics Initiates Second Phase I Study for NGX267, a Selective M1 Agonist for Treatment of Alzheimer's Disease
- UCB: Phase III Study Shows CIMZIATM is an Effective and Well-Tolerated Treatment for Crohn's Disease
- Research and Markets : Psoriasis - Biologics Impact Treatment Regimes Across The Globe
- New Treatments for Alzheimer's Disease From Rockefeller Institute
 |
 |
User Comments (0)
RSS Feeds